McAfee uncovers vulnerability in telehealth kit

By Leila Hawkins
McAfee found a vulnerability in video calling software which could be exploited to spy on live video and audio calls...

McAfee’s Advanced Threat Research (ATR) team has uncovered a new vulnerability in video calling software used by telemedicine providers. 

The security issue was discovered in Agora, a video calling software development kit (SDK) included in healthcare apps like Dr. First Backline, Talkspace and temi, and used across more than 1.7 billion devices globally. 

According to McAfee, Agora’s SDK until recently included a vulnerability that could have allowed an attacker to spy on ongoing video and audio calls. The McAfee ATR team discovered that this stemmed from an error in incomplete encryption. Agora’s SDK implementation did not allow applications to securely configure the setup of video/audio encryption, leaving a potential for hackers to snoop on them. 

If exploited, this particular vulnerability could’ve allowed a criminal to launch manin-the-middle attacks, which occur when a hacker secretly intercepts and possibly alters the communications between two unsuspecting users. 

Encryption has increasingly become the new standard for communication; often even in cases where data privacy is not explicitly sensitive. For example, all modern browsers have begun to migrate to newer standards (HTTP/2) which enforce encryption by default, a complete change from just a few years ago where a significant amount of browsing traffic was sent in clear text and could be viewed by any interested party. 

While the need to protect truly sensitive information such as financial data, health records, and other personally identifiable information (PII) has long been standardised, consumers are increasingly expecting privacy and encryption for all web traffic and applications.

In accordance with McAfee’s safe vulnerability disclosure policy, ATR provided Agora with details of its research, so that the software developer could take action to address it with a software update. Agora was very receptive to receiving this information and advanced its security capabilities, by providing developers with a new SDK option to encrypt the initial call setup information. McAfee have since tested this and confirmed there is no further risk. 

Uncovering vulnerabilities like this highlight the importance of researchers working closely with app developers to make tools as secure as possible. McAfee also recommends that consumers take care when downloading the latest apps, as software apps tend to struggle with bugs and vulnerabilities in their early days.

“McAfee is unaware of any instances of this vulnerability being exploited in the wild, which demonstrates another powerful success story of mitigating an issue which may have affected millions of users before it is used for malicious purposes” the ATR team said in a press release. 

“Our partnership with Agora resulted in the release of a more secure SDK which has empowered developers across multiple companies to produce more secure video calling applications. We strongly recommend any development team which uses the Agora SDK to upgrade to the latest version, follow Agora’s outlined best practices, and implement full encryption wherever possible.”


Featured Articles

Cylera’s Richard Staynings on healthcare cybersecurity

Richard Staynings, Chief Security Strategist, discusses the challenges facing healthcare cybersecurity & how Cylera's IoT security can protect it

Amazon Prime & One Medical to revolutionise healthcare

Amazon's vision for health is one that is affordable & convenient. Together, One Medical & Amazon Prime are a prescription for better healthcare

Creating robust pharma supply chains with delivery devices

John Swift, Head of Supply Chain at Owen Mumford Pharmaceutical Services, discusses how lifecycle management is key to a safe supply of pharma products

From Ukraine to Myanmar, reports reveal attacks on hospitals


The use of AI in biopharma according to L.E.K. Consulting

Technology & AI

Novartis Kisqali minimises breast cancer recurrence

Medical Devices & Pharma